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of acute respiratory distress
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ABSTRACT
The reported incidence of ARDS is highly
variable (2.5%–19% of intensive care unit
(ICU) patients) and varies depending on study
patient population used. We undertook a
6-month, prospective study to determine the
incidence and outcome of ARDS in a UK adult
University Hospital ICU. 344 patients were
admitted during the study period, of these 43
(12.5%) were determined to have ARDS.
Patients with ARDS had increased mortality at
28 days and 2 years post-diagnosis, and there
was under-recognition of ARDS in both
medical records and death certificattion. Our
findings have implications for critical care
resource planning.
The acute respiratory distress syndrome
(ARDS) is characterised by pulmonary
inflammation and increased pulmonary
vascular permeability, which results in
non-cardiogenic pulmonary oedema and
refractory hypoxaemia.1 ARDS is asso-
ciated with significant morbidity and mor-
tality, and increased usage of critical care
resources. The reported incidence of
ARDS is highly variable: ARDS has been
reported in 2.5%–19% of intensive care
unit (ICU) patients.2–8 Aside from an audit
conducted in 23 Scottish ICUs in 2003,
which identified an ARDS incidence of
8.1%,6 there have been no recent studies
in the UK. Reported mortality rates for
ARDS also vary substantially, with values
for inhospital mortality ranging from 23%
to 72%.9 To address this we undertook a
6-month, prospective study to determine
the incidence and outcome of ARDS in a
UK adult University Hospital ICU.
Our study was approved by
Cambridgeshire 3 Ethics Committee (08/
H0306/17) and conducted in the John V
Farman (general adult) ICU at Cambridge
University Hospitals NHS Foundation
Trust; a 20-bed ICU, serving a 1250-bed
University Hospital with a local catchment
of 350 000, and a wider regional referral
base of ∼2 million people. A dedicated
clinical research team, not involved in
patient care, prospectively studied all
patients admitted during a 6-month
period (1 January–30 June 2009). The
ICU clinical staff were not aware of the
aim of the data collection. Data were col-
lected daily until patient discharge from
ICU; patients were then followed up to
determine their date of hospital discharge,
and survival status at 28 days, 6 months
and 2 years.
All patients with a P:F ratio of <40 kPa
on two arterial blood gases, taken at least
6 hours apart, and bilateral opacities on
thoracic radiography had their medical
notes, hospital investigations and chest
radiographs reviewed by a physician who
was independent of the data collection to
confirm or exclude the diagnosis of
ARDS.10 All other patients were consi-
dered not to have ARDS (‘No Lung
Injury’, NLI). Assessment of left atrial
hypertension was based on objective cri-
teria when available. Patients were
excluded if they had any of the following:
biochemical or electrical evidence of an
acute myocardial infarction, previous or
current echocardiograms showing moder-
ate or greater dilated left atrium or left
ventricular dysfunction or an enlarged
cardiac silhouette on a recent posterior–
anterior chest radiograph. A randomly
generated sample of 40% of patients with
NLI had their cases reviewed in the same
manner as above, to confirm the absence
of ARDS. Only one case initially classified
as NLI was reclassified as ARDS. For
patients with a confirmed diagnosis of
ARDS, copies of their hospital discharge
summaries and medical coding were
obtained, and the medical death certifi-
cates of those patients who died in hos-
pital were reviewed.
Data were analysed using GraphPad
Prism. Categorical variables were
described using proportions and analysed
using Fisher exact or χ2 tests. Continuous
variables were described using median
(IQR), and analysed using Mann-Whitney
test as they were found not to follow a
Gaussian distribution. Survival curves
were compared using Mantel-Cox test.
For the purposes of calculating length of
ICU/hospital stay, the date of death was
assumed to be the date of discharge from
ICU/hospital. A p value of <0.05 was
considered significant.
Three hundred and forty-four patients
were admitted during the study period, of
these 43 (12.5%) were determined to
have ARDS (table 1). Our data are consist-
ent with the previously cited Scottish
study, and a multicentre European study
from 2002,6 7 suggesting that the UK may
not have observed the same decline in
ARDS incidence reported in US study
populations.11
There was no difference in age (median
61 vs 63 years) or sex (males: 51% vs
56.8%) between patients who had ARDS
and those who did not. The Acute
Physiology and Chronic Health
Evaluation (APACHE) II score on admis-
sion to ICU was significantly greater for
patients who had or subsequently devel-
oped ARDS, compared with patients who
did not (median 20 (17–24) vs 16 (13–
21); p<0.0001). Pulmonary sepsis was
the most common cause of ARDS, occur-
ring in 29 out of 43 cases (67.4%). Nine
cases of ARDS were associated with non-
pulmonary sepsis, four cases were transfu-
sion-associated acute lung injury (TRALI)
and one occurred in the setting of poly-
trauma. The majority of the ARDS patient
cohort (62.7%; n=27) met ARDS diag-
nostic criteria at the time of their admis-
sion to ICU.
Patients with ARDS had significantly
fewer ventilator-free days within the first
28 days following ICU admission (median
7 (0–14) vs 27 (25–28) days; p<0.0001),
and longer ICU stays than those who did
not develop ARDS (median 15 (4–23) vs
3 (2–6.5) days; p<0.0001). All study
Table 1 Incidence and outcome of ARDS in UK teaching hospital ICU
NLI ARDS p Value
n (%) 301 (87.5) 43 (12.5)
Median age in years (IQR) 63 (49–75) 61 (45–75) 0.7690
Male, n (%) 171 (56.8%) 22 (51.1%) 0.5141
Median APACHE II score on admission to ICU (IQR) 16 (13–21) 20 (17–24) <0.0001
Median length of hospital stay prior to ICU admission in days (IQR) 2 (1–7) 3 (2–18) <0.001
Median length of ICU stay in days (IQR) 3 (2–6.5) 15 (4–23) <0.0001
Median length of hospital stay in days (IQR) 23 (11–43) 38 (13–69) 0.0502
Mortality in ICU, n (%) 34 (11.3%) 18 (41.9%) <0.0001
Mortality in hospital, n (%) 64 (21.2%) 23 (53.5%) <0.0001
Mortality at 28 days, n (%) 46 (15.3%) 17 (39.5%) <0.0001
Mortality at 6 months, n (%) 73 (24.3%) 24 (55.8%) <0.0001
Mortality at 2 years, n (%) 108 (35.9%) 27 (62.8%) <0.0001
APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome; ICU, intensive care
unit; NLI, no lung injury.
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patients received standard mechanical ven-
tilation (ie, none received extracorporeal
support, high frequency oscillation or
other advanced respiratory support
modalities). There was an increased length
of hospital stay (median 38 (13–69) vs 23
(11–43) days; p=0.05) in patients with
ARDS, but this was not significant at the
5% level.
Patients with ARDS had ICU and hos-
pital mortality rates of 41.9% and 53.5%,
respectively; these were significantly
greater than the ICU and hospital morta-
lity rates for patients with NLI of 11% and
21%, respectively (p<0.001, p<0.05).
Figure 1 shows the Kaplan–Meier survival
curves for each patient group. Patients with
ARDS have a significantly reduced long-
term survival compared with patients who
had NLI (p<0.0001).
Despite a requirement that all patients,
including those who die during their
admission, admitted to our hospital
should receive a discharge summary, of
the 43 patients with ARDS, only 20 had a
completed electronic hospital discharge
summary. Remarkably, of these 20, only
one made reference to the development
of ARDS during the admission. Again, of
the patients that died prior to hospital dis-
charge, only one had a medical death cer-
tificate where ARDS was specified as a
contributing cause of death, with many
others (48%) recording ‘multiple organ
failure’ as a cause of death. The lack of
documentation on medical death certifi-
cates may reflect that patients often die of
non-pulmonary organ failure, rather than
directly from ARDS. Of the 43 patients
with ARDS, only two were coded as such
by the hospital’s coding department.
The under-recognition of ARDS by
both the clinical and coding teams, and
the omission of any reference to ARDS in
the medical correspondence may have
wide ranging implications in terms of the
immediate management for individual
patients (eg, timely commencement of
lung protective ventilation and other sup-
portive measures), and in their follow-up
care. Long-term follow-up studies have
shown that ARDS survivors suffer major
and ongoing reductions in their health/
functional status.12 Under-recognition also
has implications for resource planning
with regard to ensuring critical care facil-
ities meet demands, for example, the pro-
vision of extracorporeal membrane
oxygenation services.
A limitation of this study is the potential
for misclassification of ARDS, due in part
to the subjective nature of the diagnostic
criteria. However, to minimise this, a phys-
ician independent of the data collection
team reviewed all potential cases of ARDS,
as well as a representative 40% sample of
patients who did not. Further weaknesses
of our study include it being a single centre
study, the potential for the study nurse
involved in the prospective data collection
to influence the outcome, and the low inci-
dence of ARDS due to non-septic causes.
Despite this, our study highlights the
impact of ARDS on patient outcomes and
ICU/hospital resource usage.
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